CN
Centessa Pharmaceuticals plc
CNTA · NASDAQ
$40.50 +1.02% (+$0.41)
Market Cap $6.27B
P/E Ratio -
Div. Yield -
ROE 55.42%
Bulios Fair Price
$37.61
7.1% downside
Current Price
$40.5
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CNTA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 417.78x
P/B 12.86x
P/E N/A
Growth
100 /100
Growing Book val. growth 324.06%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 100.00%
FCF margin 1,403.96%
Net margin 1,404.07%
Quality
0 /100
Poor ROIC 36.74%
Asset turnover 0.02x
ROE 55.42%
Debt
80 /100
Low Debt/Equity 0.02x
Net debt/EBITDA 0.28x
Current ratio 9.53x
Stability
27 /100
Unstable Beta 1.12x
Profitable years 0
EPS volatility 3,115.19%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CNTA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Mario Alberto Accardi
Employees
129
Headquarters
Altrincham